Zacks: Analysts Expect Nektar Therapeutics (NKTR) Will Announce Earnings of -$0.64 Per Share

Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to report earnings per share of ($0.64) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Nektar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate coming in at ($0.73). Nektar Therapeutics reported earnings of $0.37 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 273%. The firm is scheduled to issue its next earnings results on Tuesday, November 6th.

On average, analysts expect that Nektar Therapeutics will report full-year earnings of $3.57 per share for the current fiscal year, with EPS estimates ranging from $3.22 to $3.82. For the next fiscal year, analysts forecast that the company will post earnings of ($0.98) per share, with EPS estimates ranging from ($2.69) to $4.42. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.11. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the previous year, the company posted ($0.39) earnings per share. The business’s revenue for the quarter was up 3043.7% compared to the same quarter last year.

Several analysts recently issued reports on the stock. Zacks Investment Research cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. BidaskClub cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 18th. HC Wainwright set a $54.00 price target on shares of Nektar Therapeutics and gave the company a “hold” rating in a report on Friday, August 10th. Finally, TheStreet raised shares of Nektar Therapeutics from a “d” rating to a “c” rating in a report on Wednesday, August 8th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $82.91.

In other Nektar Therapeutics news, Director R Scott Greer sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $67.39, for a total transaction of $673,900.00. Following the completion of the sale, the director now owns 140,333 shares in the company, valued at $9,457,040.87. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Dennis L. Winger sold 34,250 shares of the business’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $60.60, for a total transaction of $2,075,550.00. Following the sale, the director now owns 59,875 shares of the company’s stock, valued at approximately $3,628,425. The disclosure for this sale can be found here. Insiders sold 96,000 shares of company stock worth $5,825,680 over the last ninety days. 4.31% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Asset Management One Co. Ltd. bought a new stake in Nektar Therapeutics during the first quarter valued at $110,000. We Are One Seven LLC bought a new stake in Nektar Therapeutics during the first quarter valued at $118,000. Suntrust Banks Inc. bought a new stake in Nektar Therapeutics during the first quarter valued at $264,000. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Nektar Therapeutics during the second quarter valued at $137,000. Finally, Flagship Harbor Advisors LLC bought a new stake in Nektar Therapeutics during the second quarter valued at $142,000. Hedge funds and other institutional investors own 92.20% of the company’s stock.

Shares of NASDAQ NKTR traded up $1.01 during trading on Monday, reaching $48.91. 2,001,546 shares of the stock were exchanged, compared to its average volume of 3,167,571. Nektar Therapeutics has a twelve month low of $22.75 and a twelve month high of $111.36. The company has a current ratio of 19.67, a quick ratio of 19.55 and a debt-to-equity ratio of 0.13. The stock has a market cap of $10.51 billion, a P/E ratio of -88.93 and a beta of 2.39.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Recommended Story: Analyst Ratings

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply